Janssen to Highlight Depth of Solid Tumor Portfolio at ASCO GU
RARITAN, N.J., February 3, 2020 – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today multiple data presentations from a robust solid tumor portfolio that will be featured at the American Society of Clinical Oncology Genitourinary (ASCO GU) Cancers Symposium, taking place February 13-15 in San Francisco. Company-sponsored data presentations will include clinical results for ERLEADA® (apalutamide) and niraparib in prostate cancer; and BALVERSA™ (erdafitinib) in bladder cancer. “We are committed to improving outcomes in patients with prostate and bladder cancer where high unmet...
Source: Johnson and Johnson - February 3, 2020 Category: Pharmaceuticals Tags: Innovation Source Type: news

Less chemotherapy may have more benefit in rectal cancer
(University of Colorado Anschutz Medical Campus) GI Cancers Symposium: Colorado study of 48 patients with locally advanced rectal cancer receiving neoadjuvant chemotherapy, found that patients receiving lower-than-recommended doses in fact saw their tumors shrink more than patients receiving the full dose. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - January 30, 2020 Category: Cancer & Oncology Source Type: news

Breast Conservation After Neoadjuvant Chemotherapy Less Common in US Than Elsewhere Breast Conservation After Neoadjuvant Chemotherapy Less Common in US Than Elsewhere
Neoadjuvant systemic therapy can facilitate breast conservation in certain women with stage II and III operable breast cancer. But compared to other countries, significantly fewer women in the United States make such a choice.Reuters Health Information (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - January 15, 2020 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news

Zoledronic Acid and Neoadjuvant Chemo in HER2- Breast Cancer Zoledronic Acid and Neoadjuvant Chemo in HER2- Breast Cancer
While adjuvant bisphosphonates are associated with longer survival in postmenopausal women with breast cancer, the same cannot be said for neoadjuvant bisphosphonates.Breast Cancer Research (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - December 24, 2019 Category: Consumer Health News Tags: Hematology-Oncology Journal Article Source Type: news

European Commission approves Roche ’s Kadcyla for the adjuvant treatment of people with HER2-positive early breast cancer with residual invasive disease after neoadjuvant treatment
             Basel, 19 December 2019 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the European Commission has approved Kadcyla ® (trastuzumab emtansine) for the adjuvant (after surgery) treatment of adult patients with HER2-positive early breast cancer (eBC) who have residual invasive disease in the breast and/or lymph nodes after neoadjuvant (before surgery) taxane-based and HER2-targeted therapy.“Optimal treatment is vital for every patient with early-stage breast cancer, a setting where cures are possible,” said Levi Garraway, ...
Source: Roche Media News - December 19, 2019 Category: Pharmaceuticals Source Type: news

European Commission approves Roche ’s Kadcyla for the adjuvant treatment of people with HER2-positive early breast cancer with residual invasive disease after neoadjuvant treatment
Basel, 19 December 2019 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the European Commission has approved Kadcyla ® (trastuzumab emtansine) for the adjuvant (after surgery) treatment of adult patients with HER2-positive early breast cancer (eBC) who have residual invasive disease in the breast and/or lymph nodes after neoadjuvant (before surgery) taxane-based and HER2-targeted therapy.“Optimal treatment is vital for every patient with early-stage breast cancer, a setting where cures are possible,” said Levi Garraway, M.D., Ph.D., Roche’s Chief Medical Officer and Head of Global Product De...
Source: Roche Investor Update - December 19, 2019 Category: Pharmaceuticals Source Type: news

Omit Surgery in Early-Stage Breast Cancer? Not Yet Omit Surgery in Early-Stage Breast Cancer? Not Yet
It's an enticing idea in an age of breast cancer treatment de-escalation: omit surgery if a patient achieves what looks like a complete response to neoadjuvant chemotherapy.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - December 17, 2019 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news

Julia White, MD, Discusses Tailored Local Therapy Treatment in Breast Cancer
The professor of radiation oncology discussed these tailored treatments for when patients receive neoadjuvant chemotherapy, and they get a complete pathologic response. (Source: CancerNetwork)
Source: CancerNetwork - December 17, 2019 Category: Cancer & Oncology Authors: Julia White, MD Source Type: news

Promising New Neoadjuvant Strategy in Luminal B Breast Cancer Promising New Neoadjuvant Strategy in Luminal B Breast Cancer
The combination of ribociclib and letrozole proved to a viable alternative to standard multidrug neoadjuvant chemotherapy for women with high-risk luminal B breast cancer in an exploratory phase 2 trial.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - December 16, 2019 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news

Research affirms imaging technique's ability to characterize healthy and non-healthy tissue
(SPIE--International Society for Optics and Photonics) In an article published in the peer-reviewed SPIE publication Journal of Biomedical Optics (JBO), 'Influence of neoadjuvant chemotherapy on diffuse reflectance spectra of tissue in breast surgery specimens,' research observed across 92 ex vivo breast specimens suggests that there is little to no impact on the optical signatures of breast tissue after neoadjuvant chemotherapy. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - November 27, 2019 Category: Cancer & Oncology Source Type: news

Neoadjuvant Chemotherapy for Primary Sarcoma of the Breast Neoadjuvant Chemotherapy for Primary Sarcoma of the Breast
This case suggests that breast sarcomas could be treated in the same way as other soft tissue sarcomas in terms of adjuvant chemotherapy.Journal of Medical Case Reports (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - November 20, 2019 Category: Consumer Health News Tags: Family Medicine/Primary Care Journal Article Source Type: news

Laparoscopic Procedures Provide Better Outcomes in Gastric Cancer
Laparoscopy-assisted distal gastrectomy offered better short-term, post-surgical outcomes for patients with locally advanced gastric cancer who were undergoing neoadjuvant chemotherapy.   (Source: CancerNetwork)
Source: CancerNetwork - October 8, 2019 Category: Cancer & Oncology Authors: Dave Levitan Source Type: news

Laparoscopic Gastrectomy May Be Preferable After Gastric-Cancer Chemo Laparoscopic Gastrectomy May Be Preferable After Gastric-Cancer Chemo
In patients with locally advanced gastric cancer, laparoscopy-assisted distal gastrectomy (LADG) after neoadjuvant chemotherapy appears to offer more short-term benefits than does open gastrectomy, according to Chinese researchers.Reuters Health Information (Source: Medscape Gastroenterology Headlines)
Source: Medscape Gastroenterology Headlines - October 8, 2019 Category: Gastroenterology Tags: Hematology-Oncology News Source Type: news

Pembrolizumab Plus Chemo Boosts Response in Triple-Negative Breast Cancer
Adding the immunotherapy pembrolizumab to neoadjuvant chemotherapy improved the pathological complete response rate in patients with early triple-negative breast cancer, according to findings of a study presented at ESMO. (Source: CancerNetwork)
Source: CancerNetwork - September 30, 2019 Category: Cancer & Oncology Authors: Leah Lawrence Source Type: news

Lymphedema After Axillary Node Dissection Linked With Obesity, Longer Neoadjuvant Chemo Lymphedema After Axillary Node Dissection Linked With Obesity, Longer Neoadjuvant Chemo
Increasing body mass index and longer neoadjuvant chemotherapy (NAC) are associated with a higher risk of lymphedema in women who undergo axillary lymph node dissection, researchers say.Reuters Health Information (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - July 26, 2019 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news

Skipping Surgery in Rectal Cancer: Better or Worse? Skipping Surgery in Rectal Cancer: Better or Worse?
' Unreliable'assessment of complete clinical response after neoadjuvant chemoradiotherapy for rectal cancer means a watch-and-wait strategy should be followed with caution, suggest results of an expert debate.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - July 17, 2019 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news

' Pick the Winner' Trial in Rectal Cancer: Chemoradiation First'Pick the Winner' Trial in Rectal Cancer: Chemoradiation First
A'pick the winner'trial found that chemoradiation followed by chemo wins in total neoadjuvant therapy for locally advanced rectal cancer.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - July 5, 2019 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news

Can T-DM1 Match Chemotherapy Plus Dual Blockade in HER2+ Breast Cancer?
A phase II trial tested docetaxel, trastuzumab, and pertuzumab vs T-DM1 for the neoadjuvant treatment of HER2+ breast cancer. (Source: CancerNetwork)
Source: CancerNetwork - June 14, 2019 Category: Cancer & Oncology Authors: Dave Levitan Source Type: news

Nintedanib Worsens Outcomes Along With Chemo in Advanced Ovarian Cancer
A phase II trial showed that the addition of nintedanib to neoadjuvant chemotherapy did not benefit patients with advanced epithelial ovarian cancer. (Source: CancerNetwork)
Source: CancerNetwork - June 11, 2019 Category: Cancer & Oncology Authors: Dave Levitan Source Type: news

Novel Neoadjuvant Approach May Boost Surgical Success in Pancreatic Cancer Novel Neoadjuvant Approach May Boost Surgical Success in Pancreatic Cancer
In the majority of studied patients with locally advanced pancreatic cancer, total neoadjuvant treatment with fluorouracil, leucovorin, oxaliplatin and irinotecan (FOLFIRINOX) along with losartan and chemoradiation allowed complete tumor removal, according to a single-arm phase 2 trial.Reuters Health Information (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - June 10, 2019 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news

NRG trial suggests total neoadjuvant therapy for locally advanced rectal cancer is safe
(NRG Oncology) Results from the first experimental arm using veliparib as part of total neoadjuvant therapy (induction chemotherapy followed by chemoradiotherapy and surgery; TNT) in patients with locally advanced rectal adenocarcinoma on the NRG Oncology Phase II clinical trial NRG-GI002 were recently presented at the American Society of Clinical Oncology (ASCO) Annual Meeting. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - June 1, 2019 Category: Cancer & Oncology Source Type: news

Packing a PUNCH in Prostate Cancer: Chemo & ADT & Surgery Packing a PUNCH in Prostate Cancer: Chemo & ADT & Surgery
Investigators of the Preoperative Use of Neoadjuvant Chemotherapy (PUNCH) trial say that this experimental approach should now be a standard in high-risk, localized disease. An expert rejects the idea.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - May 7, 2019 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news

New Lesions ID'd on Breast MRI During Treatment Likely Benign
TUESDAY, May 7, 2019 -- For patients undergoing neoadjuvant chemotherapy for locally advanced breast cancer, magnetic resonance imaging (MRI) examinations with new suspicious findings are unlikely to represent a new site of malignancy, according to... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - May 7, 2019 Category: Pharmaceuticals Source Type: news

Frequency and outcomes of new suspicious lesions on breast MRI in neoadjuvant therapy
(American Roentgen Ray Society) During neoadjuvant chemotherapy, new suspicious findings detected on breast magnetic resonance imaging (MRI) during neoadjuvant therapy are most likely benign, according to a study to be presented at the ARRS 2019 Annual Meeting, set for May 5-10 in Honolulu, Hawaii. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - May 7, 2019 Category: Cancer & Oncology Source Type: news

Triple negative breast cancers can adopt reversible state that is resistant to chemotherapy
(University of Texas M. D. Anderson Cancer Center) Researchers at The University of Texas MD Anderson Cancer Center have discovered that triple negative breast cancer (TNBC) cells can develop resistance to frontline, or neoadjuvant, chemotherapy not by acquiring permanent adaptations, but rather transiently turning on molecular pathways that protect the cells. (Source: EurekAlert! - Biology)
Source: EurekAlert! - Biology - April 17, 2019 Category: Biology Source Type: news

Implication of Residual TILs in TNBC After Neoadjuvant Chemo Implication of Residual TILs in TNBC After Neoadjuvant Chemo
Do residual disease tumor-infiltrating lymphocyte levels help predict survival after neoadjuvant chemotherapy for TNBC?Annals of Oncology (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - April 15, 2019 Category: Consumer Health News Tags: Hematology-Oncology Journal Article Source Type: news

Neoadjuvant Chemotherapy Key to Survival in Pancreatic Cancer
Three factors independently linked to prolonged survival in BR/LA pancreatic ductal adenocarcinoma (Source: The Doctors Lounge - Oncology)
Source: The Doctors Lounge - Oncology - April 4, 2019 Category: Cancer & Oncology Tags: Gastroenterology, Oncology, Surgery, Journal, Source Type: news

Neoadjuvant Chemotherapy Key to Survival in Pancreatic Cancer
THURSDAY, April 4, 2019 -- Three factors can predict survival in patients with borderline resectable (BR) or locally advanced (LA) pancreatic ductal adenocarcinoma (PDAC), according to a study published online April 2 in the Annals of Surgery. Mark... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - April 4, 2019 Category: Pharmaceuticals Source Type: news

Adding an Oncolytic Virus to Neoadjuvant Chemo for Triple-Negative Breast Cancer
A small early-phase trial tested the addition of the oncolytic virus T-VEC to neoadjuvant chemotherapy in patients with triple-negative breast cancer. (Source: CancerNetwork)
Source: CancerNetwork - April 1, 2019 Category: Cancer & Oncology Authors: Dave Levitan Source Type: news

Study: Less-Invasive Mesothelioma Surgery Yields Better Results
A team of researchers at the Hyogo College of Medicine in Nishinomiya, Japan, studied the outcomes for pleural mesothelioma patients who received surgery at their facility between 2004 and 2016. The results: More aggressive surgery did not help mesothelioma patients live longer. “We showed that introducing less-invasive surgical techniques could decrease surgical risks without compromising survival,” the researchers wrote in their study, published in January in Seminars in Thoracic and Cardiovascular Surgery. “Surgery that is less invasive than conventional extrapleural pneumonectomy could achieve lower ...
Source: Asbestos and Mesothelioma News - March 14, 2019 Category: Environmental Health Authors: Matt Mauney Source Type: news

Mesothelioma Treatment Combines Proton and Photodynamic Therapy
Intraoperative photodynamic therapy combined with novel proton radiation improved survival time significantly for recent patients with advanced-stage pleural mesothelioma. The study — the first to measure the impact of this combination — involved 10 consecutive patients treated at the University of Pennsylvania’s Abramson Cancer Center. The treatment regimen resulted in a 90 percent, two-year disease control rate and an impressive 30.3-month median overall survival from the time of diagnosis. All 10 patients were diagnosed before treatment began with stage 3 or stage 4 disease, which typically results in ...
Source: Asbestos and Mesothelioma News - March 12, 2019 Category: Environmental Health Authors: Matt Mauney Source Type: news

Neoadjuvant Chemotherapy in Advanced Ovarian Cancer Neoadjuvant Chemotherapy in Advanced Ovarian Cancer
Which patients with epithelial ovarian cancer should be considered for neoadjuvant chemotherapy followed by interval debulking surgery?Chinese Clinical Oncology (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - February 28, 2019 Category: Consumer Health News Tags: Hematology-Oncology Journal Article Source Type: news

Neoadjuvant Chemo Ups Survival in Pancreatic Cancer Neoadjuvant Chemo Ups Survival in Pancreatic Cancer
Neoadjuvant chemotherapy significantly improved overall survival in a cohort of Japanese patients and could be a new treatment option, but the regimen is not currently available in the US.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - January 22, 2019 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news

Smoking Associated With Worse Bladder Cancer Outcomes
FRIDAY, Jan. 11, 2019 -- Cigarette smoking is linked to a poor response to cisplatin-based neoadjuvant chemotherapy (NAC) among patients with muscle-invasive bladder cancer (MIBC) who undergo radical cystectomy (RC), according to a study published... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - January 11, 2019 Category: Pharmaceuticals Source Type: news

Tumors backfire on chemotherapy
Some patients with breast cancer receive chemotherapy before the tumor is removed with surgery. This approach, called 'neoadjuvant' therapy, helps to reduce the size of the tumor to facilitate breast-conserving surgery, and can even eradicate the tumor, leaving few or no cancerous cells for the surgeon to remove. In those cases, the patients are very likely to remain cancer-free for life after surgery. (Source: World Pharma News)
Source: World Pharma News - January 2, 2019 Category: Pharmaceuticals Tags: Featured Research Research and Development Source Type: news

Delays to Neoadjuvant Chemotherapy Have Risks in Bladder Cancer
Several factors, including race, insurance, and type of facility, were associated with delays in neoadjuvant chemotherapy treatment for bladder cancer patients. (Source: CancerNetwork)
Source: CancerNetwork - December 12, 2018 Category: Cancer & Oncology Authors: Dave Levitan Source Type: news

Can Anthracyclines be Excluded From Neoadjuvant HER2+ Breast Cancer Tx?
A comparison of chemotherapy regimens plus anti-HER2 therapy in the neoadjuvant setting tested whether the addition of anthracyclines is necessary for patients with HER2-positive breast cancer. (Source: CancerNetwork)
Source: CancerNetwork - December 12, 2018 Category: Cancer & Oncology Authors: Dave Levitan Source Type: news

SABCS: T - DM1 Cuts Recurrent Invasive HER2 + Breast CA Risk
Risk reduced with trastuzumab emtansine in those with residual invasive dz at sx after neoadjuvant chemo (Source: The Doctors Lounge - Oncology)
Source: The Doctors Lounge - Oncology - December 5, 2018 Category: Cancer & Oncology Tags: Gynecology, Oncology, Pharmacy, Conference News, Source Type: news

Can Anthracyclines be Excluded From Neoadjuvant HER2+ Breast Cancer Tx?
A comparison of chemotherapy regimens plus anti-HER2 therapy in the neoadjuvant setting tested whether the addition of anthracyclines is necessary for patients with HER2-positive breast cancer. (Source: CancerNetwork)
Source: CancerNetwork - December 5, 2018 Category: Cancer & Oncology Authors: Dave Levitan Source Type: news

SABCS: T-DM1 Cuts Recurrent Invasive HER2 & #43; Breast CA Risk
WEDNESDAY, Dec. 5, 2018 -- For patients with residual invasive disease after neoadjuvant chemotherapy including a taxane and trastuzumab, substituting trastuzumab emtansine (T-DM1) for adjuvant trastuzumab is associated with a reduced risk for... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - December 5, 2018 Category: Pharmaceuticals Source Type: news

Phase III KATHERINE trial crossed early reporting boundary and met its primary endpoint
(American Association for Cancer Research) Substituting trastuzumab emtansine (T-DM1, Kadcyla) for adjuvant trastuzumab (Herceptin) in patients who had residual disease after receiving neoadjuvant chemotherapy and trastuzumab reduced the risk of developing an invasive recurrence of HER2-positive early-stage breast cancer by 50 percent, according to data from the phase III clinical trial KATHERINE presented at the 2018 San Antonio Breast Cancer Symposium. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - December 5, 2018 Category: Cancer & Oncology Source Type: news

Adjuvant chemo might not add benefit in breast cancer patients who have excellent response to neoadjuvant chemo
(American Association for Cancer Research) Pathological complete response (pCR) after neoadjuvant (presurgery) chemotherapy was associated with significantly lower recurrence risk and higher overall survival in breast cancer patients, and pCR after neoadjuvant chemotherapy had similar association with improved outcomes among those who received additional chemotherapy following surgery (adjuvant chemotherapy) versus those who did not, according to meta-analyses of data from 52 clinical trials, presented at the 2018 San Antonio Breast Cancer Symposium. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - December 5, 2018 Category: Cancer & Oncology Source Type: news

Neoadjuvant Chemotherapy or Upfront Surgery in Advanced Ovarian Cancer?
A pooled analysis of two randomized trials found that neoadjuvant chemotherapy and upfront debulking surgery yield similar outcomes in patients with advanced tubo-ovarian cancer, except in some settings. (Source: CancerNetwork)
Source: CancerNetwork - November 19, 2018 Category: Cancer & Oncology Authors: Dave Levitan Source Type: news

Is Controversy Over NCRT Plus Surgery Warranted in Esophageal Squamous Cell Carcinoma?
A new study adds to evidence examining whether neoadjuvant chemoradiotherapy plus surgery improves survival vs surgery alone in locally advanced ESCC. (Source: CancerNetwork)
Source: CancerNetwork - October 31, 2018 Category: Cancer & Oncology Authors: John Schieszer Source Type: news

Do Dose-Dense Neoadjuvant Chemo Regimens Improve Responses in Bladder Cancer?
A dose-dense neoadjuvant chemotherapy regimen yielded higher response rates compared with a standard regimen in a cohort of bladder cancer patients. (Source: CancerNetwork)
Source: CancerNetwork - September 19, 2018 Category: Cancer & Oncology Authors: Dave Levitan Source Type: news

Which Is Best Neoadjuvant Chemo in Bladder Cancer? Which Is Best Neoadjuvant Chemo in Bladder Cancer?
A nonstandard neoadjuvant chemotherapy was associated with higher complete response rates and more downstaging in patients with muscle-invasive bladder cancer.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - September 10, 2018 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news

Improving Surgery for Mesothelioma with Glowing Tumor Technology
Thoracic surgeon Dr. Sunil Singhal at the Abramson Cancer Center has developed glowing tumor technology that should increase the effectiveness of aggressive surgery for malignant pleural mesothelioma. Singhal has shown recently that by adding a contrast agent that makes tumor cells glow, a more complete surgery can be done. This potentially avoids the now almost-inevitable cancer recurrence. “This is a big deal. We could potentially help a lot of patients with this,” Singhal told Asbestos.com. “It could change the entire field [of surgery for mesothelioma].” Singhal and his colleagues from the Abram...
Source: Asbestos and Mesothelioma News - August 10, 2018 Category: Environmental Health Authors: Matt Mauney Source Type: news

New RCT Favors Standard of Care for Squamous Cervical Cancer New RCT Favors Standard of Care for Squamous Cervical Cancer
Neoadjuvant chemotherapy falls short of chemoradiation in this new study.Medscape Oncology (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - July 30, 2018 Category: Consumer Health News Tags: Hematology-Oncology Commentary Source Type: news

Implications of CTCs in Early Breast Cancer Implications of CTCs in Early Breast Cancer
Can CTCs be used to predict prognosis and response to neoadjuvant chemotherapy in nonmetastatic breast cancer?Journal of the National Cancer Institute (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - July 20, 2018 Category: Consumer Health News Tags: Hematology-Oncology Journal Article Source Type: news

Higher OS With Neoadjuvant Chemo-RT in Pancreatic Cancer
In PREOPANC, the 2-year survival rate was significantly higher for patients who received neoadjuvant chemoradiotherapy vs standard care. (Source: CancerNetwork)
Source: CancerNetwork - June 20, 2018 Category: Cancer & Oncology Authors: Cancer Network Editors Source Type: news